This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Achetylcholinesterase (AChE) inhibition and serum lipokines in Alzheimer’s disease: friend or foe?


Kovacs, Janos, Pákáski, Magdolna, Juhasz, Anna, Feher, Agnes, Drótos, Gergely, Fazekas, Csilla Orsike, Horvath, Tamas Laszlo, Janka, Zoltan, Kálmán, János


Neuropsychopharmacologia Hungarica: A Magyar Pszichofarmakológiai Egyesület Lapja = Official Journal Of The Hungarian Association Of Psychopharmacology, Volume: 14, No.: 1, Pages.: 19-27

Year of Publication



Throughout the natural progression of Alzheimer’s disease (AD), the body mass index (BMI) decreases. This is believed to be brought on by the disturbance in the central lipid metabolism, but the exact mechanism is yet unknown. Adipokines (adiponectin, leptin), hormones produced by the adipose tissue, change glucose and lipid metabolism, and have an anorectic effect through increasing energy consumption in the hypothalamus. The goal of our study was to examine donepezil – an acetylcholinesterase inhibitor (AChEI) currently used in AD therapy -, and to what degree it influences the serum adipokine levels and metabolic parameters of AD patients. During the self-evaluation of 26 clinically diagnosed mild to moderate AD patients, therapy with 10 mg/day donepezil was started according to current protocols. We measured serum adiponectin, leptin, LDL, HDL, trigliceride levels, and BMI and ApoE polymorphism at the beginning of our study, and at 3 and 6-months intervals respectively. All data were analyzed with SPSS 17. In comparison with pre-donepezil therapy values, at the third month interval serum adiponectin levels showed an increasing and leptin levels a decreasing tendency. At the six month interval, adiponectin levels significantly increased (p=0.007), leptin levels decreased (p=0.013), BMI (p=0.001) and abdominal circumference (p=0.017) was significantly lower at 6 months as compared to control values. We did not observe any changes in the lipid profile, and ApoE4 allele carrying showed no association with the parameters. To our knowledge, we are the first to publish that AChEI therapy with donepezil alters lipokine levels, which positively influences the currently known pathomechanism and numerous risk factors of AD. The AChEI treatment-induced weight loss should be considered in the long-term therapy of AD patients.;


adikipone, adipokines, adiponectin, administration & dosage, aged, aged, 80 and over, alzheimer disease, apolipoproteins e, appetite, biological markers, blood, body mass index, cholesterol hdl, cholesterol ldl, cholinesterase inhibitors, diagnosis, donepezil, drug administration schedule, drug therapy, female, genetics, humans, hungary, indans, leptin, levels, lipid metabolism, male, metabolic, metabolism, middle aged, nootropic agents, outpatients, parameters, piperidines, polymorphism single nucleotide, serum, severity of illness index, therapeutic use, time factors, treatment outcome, triglycerides, waist circumference

Countries of Study


Types of Dementia

Alzheimer’s Disease

Types of Study

Cohort Study

Type of Outcomes

Physical Health

Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions

Anti-Alzheimer medications, e.g.: donezepil, galantamine, rivastigmine, memantime